Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic Wistar rats

Biol Pharm Bull. 2008 Dec;31(12):2250-4. doi: 10.1248/bpb.31.2250.

Abstract

The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats. Normophagic intact Wistar rats were given fluvoxamine (100 mg/kg/d, per os (p.o.)) or vehicle for 10 d. Hyperphagic middle-aged Wistar rats were subjected to 10 d of food restriction; they were allowed to refeed for 10 d, with ad libitum food access and administered fluvoxamine (100 mg/kg/d, p.o.) or vehicle during the 10-d refeeding period. Fluvoxamine administration to normophagic middle-aged Wistar rats affected neither their weight nor food intake. However, administration to food-restricted rats showed inhibitory effects of weight gain and food intake during 10 d of refeeding. Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls. Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH. These results suggest that the appetite-controlling effect of fluvoxamine might be responsive to the rats' appetite condition.

MeSH terms

  • Animals
  • Antidepressive Agents, Second-Generation / pharmacology*
  • Body Weight / drug effects
  • Eating / drug effects*
  • Fluvoxamine / pharmacology*
  • Hyperphagia / psychology*
  • Hypothalamus / drug effects
  • Hypothalamus / physiology
  • Male
  • Neuropeptide Y / physiology
  • Rats
  • Rats, Wistar
  • Weight Gain / drug effects*

Substances

  • Antidepressive Agents, Second-Generation
  • Neuropeptide Y
  • Fluvoxamine